Our advanced image analysis technology allows segmentation of lung structures like airways and blood vessels as well as detection of abnormalities in the lung parenchyma linked to multiple lung diseases. The quantification of these segmentations allows to measure and follow-up the presence and the extent of conditions like COVID-19, influenza, ILDs, COPD, asthma, and others.

We demonstrated that radiomics quantifications are useful tools in optimizing the clinical drug development trajectory, daily patient management or to generate additional insights in respiratory research.
Radiomics developed COVIA, an urgency CE class 1 software as medical device for the diagnosis of COVID-19 infection during pandemic conditions from CT scans and is currently actively involved in research on fibrosis, pulmonary embolism & hypertension, and emphysema.

Solid tumors
Radiomics quantifications
Pancancer approach

Other diseases and therapeutic areas